Doctor and patient


Sareum was founded in August 2003 as a spin out from Millennium Pharmaceuticals' Structure-Based Discovery Department. Following an initial private investment, the company was successfully admitted to the Alternative Investment Market (AIM) of the London Stock Exchange in October 2004.

Since 2008, the company has focused on developing its drug discovery programmes operating with an outsourced and collaborative business model.

Find out more about how we work.

  • @Sareumplc Latest tweet

    RT @HybridanLLP: Good to see Sareum's research on TYK2 as an oncology target referenced here. We see Sareum as a frontrunner in this space… via @Sareumplc
    View more